autologous anti-ROR1 CAR T cells LYL797

A preparation of genetically and epigenetically reprogrammed autologous T lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the autologous anti-ROR1 CAR T cells LYL797 are reintroduced into the patient and are directed to tumor cells expressing ROR1, which may result in a selective toxicity against, and lysis of ROR1-expressing tumor cells. ROR1 is expressed during embryogenesis and upregulated in certain tumor types. High levels of ROR1 expression often correlate with poor prognosis. Due to the genetically and epigenetically modifications, LYL797 may overcome T-cell exhaustion and inability to self-renew. The T cells are genetically modified to overexpress the protein c-Jun and thereby resist exhaustion and restore their anti-tumor activity. Also, the T cells are reprogrammed to give them durable stemness and effector function.